BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.

Expression of the cancer-germline (CG) (or cancer-testis) antigen gene BORIS/CTCFL has been proposed to mediate activation of CG antigen genes in cancer. Consistent with this idea, we have observed that BORIS is frequently expressed in ovarian cancer, often in conjunction with other CG genes. Here we assessed the role of BORIS in CG antigen gene regulation and DNA methylation using normal and cancerous ovarian cell lines, and the CG genes MAGE-A1, NY-ESO-1, and XAGE-1 as models. Adenoviral vectored BORIS was expressed at robust levels and exhibited predominant nuclear localization in ovarian cells. However, BORIS expression in immortalized ovarian surface epithelial cells or ovarian cancer cell lines did not induce CG antigen gene expression or lead to CG antigen promoter DNA hypomethylation. BORIS overexpression also did not alter global DNA methylation, as assessed by genomic 5-methyl-deoxycytidine levels and LINE-1 methylation. We used decitabine to further assess the role of BORIS in CG gene activation and found that decitabine treatment induced BORIS and other CG genes with similar kinetics, suggesting that BORIS induction does not account for the induction of other CG genes by decitabine in ovarian cancer cells. In agreement, siRNA knockdown of BORIS did not block decitabine-mediated induction of CG genes or DNA hypomethylation in ovarian cancer cells treated with this agent. We conclude that BORIS is insufficient for CG antigen gene expression and DNA hypomethylation in ovarian cell lines, and that additional factors are likely required for CG antigen expression in ovarian cancer.

[1]  R. Vessella,et al.  Expression of cancer/testis antigens in prostate cancer is associated with disease progression , 2010, The Prostate.

[2]  T. Yawata,et al.  Enhanced expression of cancer testis antigen genes in glioma stem cells , 2010, Molecular carcinogenesis.

[3]  K. Odunsi,et al.  Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. , 2010, Future oncology.

[4]  A. Loriot,et al.  DNA hypomethylation in cancer: Epigenetic scars of a neoplastic journey , 2010, Epigenetics.

[5]  P. Yaswen,et al.  BORIS (CTCFL) Is Not Expressed in Most Human Breast Cell Lines and High Grade Breast Carcinomas , 2010, PloS one.

[6]  Victor V Lobanenkov,et al.  Expression of a Testis-Specific Form of Gal3st1 (CST), a Gene Essential for Spermatogenesis, Is Regulated by the CTCF Paralogous Gene BORIS , 2010, Molecular and Cellular Biology.

[7]  N. Brünner,et al.  High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression , 2009, BMC Cancer.

[8]  S. Khochbin,et al.  New hypotheses for large-scale epigenome alterations in somatic cancer cells: a role for male germ-cell-specific regulators. , 2009, Epigenomics.

[9]  J. Karbach,et al.  Tumor‐reactive CD8+ T‐cell responses after vaccination with NY‐ESO‐1 peptide, CpG 7909 and Montanide® ISA‐51: association with survival , 2009, International journal of cancer.

[10]  O. Gangisetty,et al.  Distinct Roles for Histone Methyltransferases G9a and GLP in Cancer Germ-Line Antigen Gene Regulation in Human Cancer Cells and Murine Embryonic Stem Cells , 2009, Molecular Cancer Research.

[11]  Steven S. Chang,et al.  Coordinated Activation of Candidate Proto-Oncogenes and Cancer Testes Antigens via Promoter Demethylation in Head and Neck Cancer and Lung Cancer , 2009, PloS one.

[12]  K. Odunsi,et al.  Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer , 2008, Clinical Cancer Research.

[13]  A. Iasonos,et al.  Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission , 2008, Clinical Cancer Research.

[14]  F. Brasseur,et al.  Expression of BORIS in melanoma: Lack of association with MAGE‐A1 activation , 2008, International journal of cancer.

[15]  K. Odunsi,et al.  Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[16]  K. Pantel,et al.  Methyl-CpG Binding Domain Proteins and Their Involvement in the Regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 Gene Promoters , 2007, Molecular Cancer Research.

[17]  Chao-jun Song,et al.  [Preparation of the monoclonal antibodies against human BORIS and the expression pattern of BORIS in normal and diseased human mammary tissues]. , 2007, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.

[18]  W. Schulz,et al.  Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. , 2006, Biochemical pharmacology.

[19]  Petra A. Link,et al.  Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b , 2006, Oncogene.

[20]  A. Karpf.  A Potential Role for Epigenetic Modulatory Drugs in the Enhancement of Cancer/Germ-Line Antigen Vaccine Efficacy , 2006, Epigenetics.

[21]  K. Pantel,et al.  Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells , 2006, Molecular Cancer Research.

[22]  T. Boon,et al.  Transient Down-regulation of DNMT1 Methyltransferase Leads to Activation and Stable Hypomethylation of MAGE-A1 in Melanoma Cells* , 2006, Journal of Biological Chemistry.

[23]  Victor V Lobanenkov,et al.  Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. , 2005, Cancer research.

[24]  Victor V Lobanenkov,et al.  Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. , 2005, Cancer research.

[25]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[26]  K. Robertson.  DNA methylation and human disease , 2005, Nature Reviews Genetics.

[27]  Liguo Song,et al.  Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. , 2005, Analytical chemistry.

[28]  K. Roemer,et al.  Frequent Nonrandom Activation of Germ-Line Genes in Human Cancer , 2004, Cancer Research.

[29]  K. Irvine,et al.  Glycosylation regulates Notch signalling , 2003, Nature Reviews Molecular Cell Biology.

[30]  Victor V Lobanenkov,et al.  The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. , 2002, Seminars in cancer biology.

[31]  J. J. Breen,et al.  BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Bert Vogelstein,et al.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells , 2002, Nature.

[33]  F. Marincola,et al.  Sequential 5-Aza-2′-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1 , 2001, Journal of immunotherapy.

[34]  Thierry Boon,et al.  DNA Methylation Is the Primary Silencing Mechanism for a Set of Germ Line- and Tumor-Specific Genes with a CpG-Rich Promoter , 1999, Molecular and Cellular Biology.

[35]  M. Herlyn,et al.  Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. , 1994, Cancer research.

[36]  K. Odunsi,et al.  DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. , 2007, Cancer immunity.

[37]  David A Jones,et al.  Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. , 2004, Molecular pharmacology.